Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.
about
Differential activation of peritoneal cells by subcutaneous treatment of rats with cryptococcal antigensCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cationsEffects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitisAssimilation of xylose, mannose, and mannitol for synthesis of glucuronoxylomannan of Cryptococcus neoformans determined by 13C nuclear magnetic resonance spectroscopy.Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus GalactomannanAntibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo.Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural networkIn vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune micePhenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous systemContribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophilsMonoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigenDetermination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsuleCryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cellsPeptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 geneAcute lethal toxicity following passive immunization for treatment of murine cryptococcosisReactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.Parallel beta-helix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans.Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformansChitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown propertiesCytokine patterns in a prospective cohort of HIV-infected patients with cryptococcal meningitis following initiation of antifungal and antiretroviral therapyProtective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.Serotyping of Cryptococcus neoformans by dot enzyme assay.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannanThe glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigenGalactoxylomannans of Cryptococcus neoformans.Macrophage uptake, intracellular localization, and degradation of poly-gamma-D-glutamic acid, the capsular antigen of Bacillus anthracis.Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.Purification of the 115-kilodalton exoantigen of Cryptococcus neoformans and its recognition by immune sera.
P2860
Q28573435-B6C3DB37-3242-4973-8EB5-BBDA69229EDFQ30424017-3BC42EED-2F94-471D-B40F-62E36F966BFEQ30479935-721EB9EB-57B6-4829-8BE9-5ABE7A076ECAQ33556039-E7031014-9B21-4383-8122-36C88C3B5EB8Q33602561-B5095D34-DED0-437E-A852-BB5405D35056Q33619785-6EC307F9-5DB9-48D7-90FC-5B06E64AE6F9Q33716133-6EA58A82-68DB-46CC-9D97-452A5ABB6918Q33755667-985B6070-5E7C-4BD7-BFE5-8EB98699D5A3Q33856355-205CFFF3-7C7F-4043-BD9E-14DCE7D5457EQ33909453-633C96C4-4DFE-44F6-A0FE-151B113B1933Q33939999-0E2546D1-693D-4A19-96C1-528C83D047F8Q33991281-A66DF511-74E5-45CB-BE2C-3BF43C1A9D0CQ34001243-A1D8EE04-9640-4AE6-88FD-7E5ED01F6D3FQ34001701-2E3EAEF2-E4AA-4C4C-B1EC-F0E527877A22Q34334384-898041D3-1448-48E1-8FA1-8E68B4ABE9AEQ34779166-7D5E2EE8-2A40-4298-AAB0-8F9C94FADDC9Q35011899-2F5AB0FF-78A1-4C4C-AF17-FC51D1B00998Q35138768-7F358A7F-8253-46A2-AF84-F059C42D8D95Q35409786-4AFA4FAA-1485-4040-A102-FC3DFE3ECD6FQ35411136-E6097012-9061-4B11-B894-37D99A097733Q35434901-9322DB14-1E96-4498-AF91-67B4F80274DFQ35449775-B79E2ADD-C15E-4F86-9AE8-3D05E3087E9CQ35534083-6B0D88A3-1B8E-4E83-BA6F-18FB11757377Q35544888-C78B6D8C-37FF-4D0F-B834-8E89AF06E995Q35546019-0FEA8EBD-CF2E-44F9-93D1-1FEDFBAAE04BQ35546751-29DE36C4-5D88-407D-97BE-7438267500B1Q35567548-94827C4C-31E7-4EB5-A011-24146F683EFFQ35641043-316A3228-56E0-4A9C-ABAE-60218B41D652Q35783648-74554E23-CBFC-4E50-8365-CA8A63C83C4EQ35923662-38029435-E18D-47C1-8944-DCC036853BFEQ36244332-E1FD28A6-4B8B-45F4-AAE2-A446B11287BBQ36366992-A4F13D58-769C-4273-96F6-A5A8E5645212Q36446429-0E24D510-F2F8-4A85-9E15-38AC184CDFBEQ36527966-ABCDE85C-BFEE-4B81-9B13-881C790E032AQ36844895-FD9A40BA-C97A-482E-AE96-BB797583716DQ36951576-33616E68-0CFB-4FCB-BA20-D3B67D9B6F46Q36956261-2792CA9D-9F00-422F-AC2D-DF9DAA236736Q37032981-A8503965-8BD9-4E81-8845-558C8EE93482Q37051210-42AF58C2-FF15-4749-A874-67B555F1237BQ37064111-3986D245-4A49-4109-B7E0-96E941646CEA
P2860
Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Facilitated isolation, purific ...... an of Cryptococcus neoformans.
@en
type
label
Facilitated isolation, purific ...... an of Cryptococcus neoformans.
@en
prefLabel
Facilitated isolation, purific ...... an of Cryptococcus neoformans.
@en
P2093
P2860
P1476
Facilitated isolation, purific ...... an of Cryptococcus neoformans.
@en
P2093
B C Anderson
L C Morris
R Cherniak
P2860
P407
P577
1991-01-01T00:00:00Z